Pfizer and Arvinas Secure First PROTAC Approval in Breast Cancer
The FDA approved Veppanu, a first-of-its-kind PROTAC pill from Pfizer and Arvinas, for advanced breast cancer with ESR1 mutations. The decision precedes Pfizer's Q1 earnings report.
Markets
